Respiratory

Small cell lung cancer: management overview

Clinical Overview and When to Suspect Small Cell Lung Cancer

— Limited-stage (LS-SCLC): confined to one hemithorax, encompassable in a single radiation port (~30% at diagnosis).

— Extensive-stage (ES-SCLC): any spread beyond — contralateral lung, malignant effusion, distant mets (~70% at diagnosis).

— Rapidly progressive cough, hemoptysis, dyspnea, weight loss over weeks, not months.

— Bulky central/hilar mass with mediastinal adenopathy on imaging.

— SVC syndrome (facial/upper extremity edema, distended neck veins) — SCLC is the #1 malignant cause.

— Paraneoplastic syndromes: SIADH (hyponatremia), ectopic ACTH (hypokalemic alkalosis, hyperglycemia, hypertension, proximal weakness), Lambert-Eaton myasthenic syndrome (LEMS), paraneoplastic cerebellar degeneration, limbic encephalitis (anti-Hu).

Board pearl: A heavy smoker with hyponatremia (Na 118), euvolemia, urine osm > serum osm, and a central lung mass = SIADH from SCLC until proven otherwise. Order chest CT and pursue tissue diagnosis — do not just treat the sodium.

Key distinction: Non-small cell lung cancer (NSCLC) is staged by TNM and often resected; SCLC is rarely surgical and is treated as a systemic disease from day one even in "limited" stage.

Small cell lung cancer (SCLC) accounts for ~13–15% of lung cancers in the US and is strongly tobacco-associated — >95% of patients are current or former heavy smokers.

Aggressive neuroendocrine tumor arising centrally from bronchial epithelium; rapid doubling time, early hematogenous spread, and high initial chemo/radiosensitivity that is rarely durable.

Two-stage system still drives therapy:

Suspect SCLC in a smoker (≥30 pack-years, age 50–80) presenting with:

Step 3 framing: SCLC questions almost always pivot on (a) recognizing a paraneoplastic presentation, (b) staging-driven treatment choice, or (c) survivorship/PCI decisions.

Presentation Patterns and Key History

— Persistent cough (new or changed in a smoker), hemoptysis, post-obstructive pneumonia that recurs in the same lobe.

— Dyspnea from airway compression, pleural effusion, or lymphangitic spread.

— Hoarseness (left recurrent laryngeal nerve invasion at aortopulmonary window).

— Dysphagia (esophageal compression), stridor (tracheal compression).

— New seizure, focal neuro deficit, headache → brain mets.

— RUQ pain, jaundice, elevated alk phos → liver.

— Back pain, pathologic fracture, hypercalcemia → bone.

— Pancytopenia → marrow infiltration.

— Proximal leg weakness that improves with repeated effort + dry mouth + areflexia → LEMS (anti-VGCC antibodies).

— Subacute confusion, short-term memory loss, temporal lobe seizures → limbic encephalitis (anti-Hu).

— Truncal ataxia, dysarthria → paraneoplastic cerebellar degeneration.

— Easy bruising, cushingoid features over weeks (too fast for pituitary Cushing) → ectopic ACTH.

Step 3 management: When LEMS is suspected, do not stop at the neuro diagnosis — order chest CT to find the underlying SCLC; ~50–60% of LEMS cases harbor SCLC, often discoverable before or within 2 years of neuro symptoms.

Tempo is the giveaway — symptoms typically evolve over 8–12 weeks, far faster than NSCLC. A patient who "was fine 2 months ago" with a new bulky mediastinal mass should raise SCLC suspicion.

Pulmonary/local symptoms:

SVC syndrome features: dyspnea worse when leaning forward, headache, facial plethora, visual changes, Pemberton sign (facial flushing with arms raised).

Constitutional: weight loss >5%, anorexia, fatigue, fevers.

Metastatic clues — SCLC loves brain, liver, adrenals, bone, bone marrow:

Paraneoplastic histories to mine:

Key social history: quantify pack-years, occupational exposures (radon, asbestos, uranium — synergistic with smoking), family history of lung cancer.

Physical Exam Findings and Hemodynamic Assessment

— Facial plethora, periorbital edema, distended neck and chest wall veins → SVC obstruction.

— Horner syndrome (ptosis, miosis, anhidrosis) — rare in SCLC vs Pancoast NSCLC, but possible with apical disease.

— Supraclavicular lymphadenopathy (Virchow node on left, scalene nodes) — easy biopsy target.

— Hoarseness on voice testing; cushingoid moon face/buffalo hump in ectopic ACTH.

— Dullness to percussion + decreased breath sounds + decreased fremitus → pleural effusion (often malignant).

— Localized wheeze or stridor that does not clear with cough → fixed airway obstruction.

— Post-obstructive consolidation: bronchial breath sounds, egophony.

— In SVC syndrome, assess airway and cerebral edema first — these dictate urgency.

— Pulsus paradoxus, muffled heart sounds, JVD → malignant pericardial effusion/tamponade (oncologic emergency).

— Hypotension + hyperpigmentation can occur with adrenal metastases causing adrenal insufficiency.

— Proximal muscle weakness with post-exercise facilitation and hyporeflexia that improves after sustained contraction → LEMS.

— Focal deficits, papilledema → brain mets/increased ICP.

— Cerebellar signs, opsoclonus-myoclonus.

CCS pearl: In a patient with suspected SVC syndrome, your CCS order set should include head elevation, supplemental O2, IV access in the lower extremity (not the arm), urgent contrast-enhanced chest CT, and dexamethasone only if airway compromise or cerebral edema. Do not give empiric steroids if lymphoma is still on the differential and biopsy is pending — steroids can obscure histology.

General appearance: cachexia, temporal wasting, tobacco staining of fingers, clubbing (less common in SCLC than NSCLC).

Head and neck:

Pulmonary exam:

Cardiovascular/hemodynamic:

Abdominal: hepatomegaly, RUQ tenderness (liver mets).

Neurologic:

Skin: acanthosis nigricans, dermatomyositis findings (Gottron papules, heliotrope rash) — paraneoplastic.

Diagnostic Workup — Initial Labs, Imaging, and Biomarkers

— CBC with differential — anemia, cytopenias suggest marrow involvement.

— CMP — hyponatremia (SIADH), hypokalemia/alkalosis/hyperglycemia (ectopic ACTH), hypercalcemia (less common in SCLC than squamous NSCLC; if present, think bone mets), elevated LDH (prognostic), elevated alk phos/AST/ALT (liver or bone mets).

— LDH is independently prognostic in SCLC — incorporate into baseline.

— Coags, type and screen if procedures planned.

— HIV if risk factors (affects treatment tolerance).

— Contrast-enhanced CT chest/abdomen/pelvis is the first comprehensive staging study — assess primary, mediastinum, liver, adrenals.

— MRI brain with contrast is mandatory in all SCLC patients at baseline — ~10–15% have brain mets at diagnosis, often asymptomatic, and findings change therapy.

— PET/CT (FDG) to detect occult mets, especially when limited-stage is being considered for chemoradiation — upstaging occurs in ~10–20%.

— Bone scan is now largely replaced by PET; obtain if PET unavailable and bone mets suspected.

Board pearl: A new SCLC diagnosis without an MRI brain is an incomplete staging workup. On Step 3, choosing "MRI brain with contrast" over "CT head" is almost always the correct next step in newly diagnosed SCLC, regardless of neuro symptoms.

Key distinction: Tumor markers (NSE, ProGRP, chromogranin A) are not routinely used for SCLC diagnosis or surveillance in US guidelines — they are not exam answers for screening.

Initial labs (drive both diagnosis and paraneoplastic detection):

Urine studies: urine osm and urine Na to confirm SIADH workup; 24-hr urine cortisol or late-night salivary cortisol if Cushingoid.

Imaging:

ECG and echocardiogram if anthracycline-free regimens being chosen anyway, but baseline cardiac assessment is prudent given chemo and possible thoracic RT.

Pulmonary function tests (PFTs) before thoracic radiotherapy — DLCO and FEV1 affect RT planning.

Diagnostic Workup — Tissue Diagnosis and Confirmatory Studies

— Supraclavicular or palpable peripheral node → FNA/core, often outpatient under ultrasound.

— Endobronchial ultrasound–guided transbronchial needle aspiration (EBUS-TBNA) for central masses and mediastinal nodes — preferred for most SCLC because tumors are typically central; simultaneously samples N2/N3 nodes for staging.

— CT-guided transthoracic biopsy for peripheral lesions inaccessible bronchoscopically.

— Thoracentesis with cytology + cell block if pleural effusion present — a malignant effusion automatically makes the disease extensive-stage.

— Liver or bone marrow biopsy if those are the safest accessible disease sites.

— Small, round-to-fusiform cells with scant cytoplasm, finely granular "salt-and-pepper" chromatin, inconspicuous nucleoli, nuclear molding, crush artifact, high mitotic rate, extensive necrosis.

— IHC: positive for synaptophysin, chromogranin A, CD56, INSM1; TTF-1 positive in ~85%; Ki-67 typically >50–80%.

— Distinguish from large-cell neuroendocrine carcinoma, carcinoid, lymphoma, and Merkel cell metastasis when morphology is ambiguous.

Step 3 management: If a pleural effusion is seen on imaging, always sample it before declaring limited-stage disease — a positive cytology converts the patient to extensive-stage and changes you from curative-intent chemoRT to palliative chemoimmunotherapy.

Histology is required — clinical/radiographic suspicion is never enough to start chemo.

Biopsy strategy (pick the easiest, highest-yield, lowest-risk site):

Pathology features:

Molecular testing: Unlike NSCLC, routine EGFR/ALK/ROS1/PD-L1 testing is NOT standard in SCLC — driver mutations are uncommon and do not change first-line therapy. Do not order broad NGS reflexively on Step 3 — it's a distractor.

Staging confirmation: Combine pathology + imaging (CT, PET, MRI brain) to assign Limited vs Extensive stage. Bone marrow biopsy is now rarely needed unless unexplained cytopenias.

Risk Stratification and First-Line Management Logic

— Limited-stage SCLC (LS-SCLC): disease confined to one hemithorax, including ipsilateral mediastinal/supraclavicular nodes, encompassable in one tolerable RT port; no malignant effusion, no distant mets. Goal = curative intent.

— Extensive-stage SCLC (ES-SCLC): anything beyond. Goal = palliative, life-prolonging.

— ECOG 0–2 → standard-intensity platinum doublet ± RT ± immunotherapy.

— ECOG 3–4 due to tumor burden may still benefit from chemo (often dramatic response); ECOG 3–4 from comorbidity → best supportive care or dose-reduced regimens.

— SVC syndrome — start chemo urgently (SCLC is exquisitely sensitive); endovascular stent if airway/cerebral compromise.

— Symptomatic brain mets — whole-brain RT or SRS + dexamethasone.

— Spinal cord compression — dexamethasone + emergent RT/neurosurgery consult.

— Tumor lysis syndrome — pretreat with hydration, allopurinol or rasburicase given high tumor burden and chemosensitivity.

— Hyponatremia from SIADH — fluid restriction; correct slowly (≤8–10 mEq/L per 24 hrs to avoid osmotic demyelination); chemo itself often resolves it.

— LS-SCLC with chemoRT: median ~25–30 months, 5-yr OS ~30–35%.

— ES-SCLC with chemoimmunotherapy: median ~12–13 months, 5-yr OS <10%.

Board pearl: SCLC is one of the few solid tumors where starting chemotherapy is itself the emergency intervention for SVC syndrome or symptomatic disease — responses occur within days.

Key distinction: Surgery has a very narrow role — only clinical stage T1-2N0M0 (rare, <5%) after rigorous mediastinal staging, followed by adjuvant chemo ± PCI.

Stage drives everything. After tissue diagnosis + complete staging (CT C/A/P, PET, MRI brain, labs), categorize:

Performance status (ECOG/KPS) and organ function determine intensity:

Oncologic emergencies to address before or alongside therapy:

Median survival benchmarks (counseling):

Pharmacotherapy — First-Line Regimens

— Cisplatin + etoposide (EP) × 4 cycles is the backbone (cisplatin 60–80 mg/m² day 1 + etoposide 100 mg/m² days 1–3, every 21 days).

— Carboplatin + etoposide if cisplatin contraindicated (renal impairment, neuropathy, hearing loss, poor PS, elderly) — non-inferior in many analyses with less toxicity.

— Thoracic RT started early (with cycle 1 or 2) of chemo; preferred regimen is 45 Gy in 1.5 Gy twice-daily fractions over 3 weeks (Turrisi) or 60–70 Gy once-daily.

— No immunotherapy added in LS-SCLC standard of care yet in most current US practice — but durvalumab consolidation after chemoRT is emerging (ADRIATIC trial) and may be tested on future boards.

— Platinum (carboplatin preferred) + etoposide + PD-L1 inhibitor (atezolizumab or durvalumab) × 4 cycles, then maintenance immunotherapy every 3–4 weeks until progression/toxicity.

— Trials: IMpower133 (atezolizumab), CASPIAN (durvalumab) — both showed OS benefit over chemo alone.

— Cisplatin: nephrotoxicity (hydrate aggressively, avoid NSAIDs), ototoxicity, peripheral neuropathy, severe nausea (3-drug antiemetic: 5-HT3 antagonist + NK1 antagonist + dexamethasone).

— Carboplatin: myelosuppression (thrombocytopenia prominent), less emetogenic.

— Etoposide: myelosuppression, alopecia, secondary leukemia (long-term).

— Immune checkpoint inhibitors: immune-related AEs — pneumonitis, colitis, hepatitis, thyroiditis, hypophysitis, adrenalitis, type 1 DM, myocarditis. Manage with hold + high-dose steroids for grade ≥2–3; permanent discontinuation for grade 4 or recurrent.

Step 3 management: Before each cisplatin cycle, verify CrCl ≥60, audiogram if baseline hearing loss, and use 2–3 L IV saline pre/post with mannitol or furosemide per protocol to protect kidneys.

LS-SCLC first-line: concurrent chemoradiotherapy

ES-SCLC first-line: chemoimmunotherapy

Key toxicities to anticipate and monitor:

Second-line options (after relapse): lurbinectedin, topotecan, re-challenge with platinum/etoposide if platinum-sensitive relapse (≥6 months since first-line), tarlatamab (DLL3-targeted bispecific) for relapsed ES-SCLC.

Radiation Therapy and Procedural Management

— Concurrent with chemo beats sequential (better OS).

— Early initiation (cycle 1–2) beats late.

— Hyperfractionated 45 Gy BID over 3 weeks vs 60–70 Gy daily over 6–7 weeks — both acceptable; BID has more esophagitis but classic OS data.

— Toxicities: esophagitis (peaks weeks 3–5; manage with viscous lidocaine, PPI, nutrition support), radiation pneumonitis (weeks to months later; treat with steroids), cardiac toxicity (mind heart dose).

— LS-SCLC with complete or near-complete response to chemoRT → offer PCI 25 Gy in 10 fractions — reduces brain met incidence and improves OS.

— ES-SCLC with response to systemic therapy → PCI is controversial; alternative is active MRI surveillance every 3 months, which Japanese trial (Takahashi) showed non-inferior OS to PCI.

— Contraindications: poor PS, dementia, prior cranial RT, patient declines neurocognitive risk.

— Discuss neurocognitive toxicity (memory, executive function); hippocampal-avoidance PCI + memantine mitigate decline.

— Endobronchial stenting, debulking, or RT for obstructive airway disease/hemoptysis.

— SVC stenting for refractory SVC syndrome not responding to chemo.

— Pleurodesis or tunneled pleural catheter for recurrent malignant effusion.

— Whole-brain RT or stereotactic radiosurgery for symptomatic brain mets.

— Palliative RT for painful bone mets, cord compression.

CCS pearl: Order PFTs and a baseline neurocognitive assessment before PCI. Document the shared decision-making conversation about cognitive risks in your CCS note — it is a high-yield ethics/communication item.

Thoracic radiotherapy (TRT) in LS-SCLC is curative-intent and integral, not adjunctive:

Prophylactic cranial irradiation (PCI):

Palliative procedures in ES-SCLC:

Surgical resection — only for highly selected clinical T1-2N0M0 after invasive mediastinal staging (mediastinoscopy or EBUS confirming N0); followed by adjuvant 4 cycles EP and consideration of PCI. Lobectomy + mediastinal LN dissection is the standard, not wedge.

Special Populations — Elderly and Renal/Hepatic Impairment

— Geriatric assessment (G8, CARG score, or comprehensive geriatric assessment) better predicts tolerance than chronological age.

— Fit elderly with ECOG 0–1 → standard carboplatin + etoposide ± immunotherapy with full doses.

— Frail elderly → consider dose attenuation (carboplatin AUC 4–5 instead of 5–6), shorter courses, or single-agent etoposide; weigh QOL.

— Polypharmacy review mandatory — drug-drug interactions with antiemetics (QT-prolonging 5-HT3 antagonists), anticoagulants, CYP3A4 substrates (etoposide metabolism).

— Falls risk increases with neuropathy, anemia, brain mets — proactive PT referral.

— Cisplatin contraindicated if CrCl <60 (some use <50 cutoff); substitute carboplatin, dose by Calvert formula (AUC × [GFR + 25]).

— Avoid concurrent nephrotoxins (NSAIDs, aminoglycosides, IV contrast when possible).

— Hyponatremia management in CKD requires extra caution — slower correction, attention to volume status.

— Etoposide is hepatically cleared — dose reduce if bilirubin >1.5× ULN or AST elevated; hold if bilirubin >3 until clarified.

— Liver mets themselves can cause cholestasis — distinguishing from drug-induced injury matters for treatment continuation.

— Immunotherapy-induced hepatitis: rule out viral hepatitis, biliary obstruction, progression before attributing to checkpoint inhibitor; grade ≥2 → hold ICI + steroids.

Board pearl: A 78-year-old with ES-SCLC, CrCl 45, ECOG 1 should receive carboplatin (AUC 5) + etoposide + atezolizumab, not cisplatin. Choosing cisplatin in this scenario is the wrong-answer distractor.

Step 3 management: Always recalculate creatinine clearance before every cisplatin cycle in older adults — serum Cr alone underestimates renal dysfunction in low-muscle-mass patients.

Elderly patients (≥70 years) make up a large fraction of SCLC diagnoses — undertreatment is common but often unjustified by age alone.

Renal impairment:

Hepatic impairment:

Cardiac comorbidity: Baseline echo if anthracycline considered (rare in SCLC); monitor for ICI myocarditis — troponin, ECG at any new cardiopulmonary symptoms.

Special Populations — Pregnancy, Never-Smokers, and Other Subgroups

— First trimester — chemo causes teratogenicity; discuss termination vs delay; if patient continues pregnancy, defer chemo to second trimester if possible.

— Second/third trimester — platinum + etoposide is feasible with relatively low fetal risk; avoid within 3 weeks of expected delivery to prevent neonatal cytopenias.

— Radiation to chest/pelvis is contraindicated during pregnancy due to fetal scatter dose.

— Immunotherapy contraindicated — PD-L1 inhibitors cross placenta and disrupt maternal-fetal tolerance, risking miscarriage.

— Multidisciplinary team: oncology, MFM, neonatology, ethics, palliative care.

— Combined SCLC/NSCLC histology with transformation potential.

— EGFR-mutant NSCLC after TKI therapy transforming to SCLC — order EGFR testing in this scenario; treat as SCLC but with attention to the prior NSCLC trajectory.

— Hereditary syndromes (rare) — Li-Fraumeni, retinoblastoma survivors.

Key distinction: A patient previously on osimertinib for EGFR-mutant NSCLC who develops rapid progression with new high LDH and bulky disease — rebiopsy to look for small cell transformation, a recognized resistance mechanism. Switch to SCLC-style chemo.

Pregnancy: SCLC in pregnancy is exceedingly rare (median age ~70, near-universal smoking history), but principles apply:

Never-smokers with SCLC: very rare (<2%). Re-examine the diagnosis — consider:

Patients with autoimmune disease: Pre-existing autoimmunity is a relative contraindication to checkpoint inhibitors — discuss flare risk with rheumatology; if disease is stable off immunosuppression, ICIs can often be cautiously used.

HIV+ patients: Generally tolerate platinum/etoposide if CD4 >200; ICIs are increasingly used safely. Coordinate with ID for ART interactions (etoposide-CYP3A4).

Transplant recipients: Solid organ transplant is a strong contraindication to ICIs (rejection risk up to 40%). Chemo alone preferred.

LGBTQ+ and rural patients: Address access to thoracic oncology centers, telemedicine follow-up, smoking cessation resources.

Complications and Adverse Outcomes

— SVC syndrome — facial/upper extremity edema, dyspnea, headache; airway compromise and cerebral edema are emergencies.

— Malignant pleural effusion — recurrent dyspnea; tunneled catheter or pleurodesis.

— Pericardial effusion/tamponade — Beck triad, pulsus paradoxus; urgent pericardiocentesis.

— Spinal cord compression — back pain preceding neuro deficits; emergent MRI, dexamethasone, RT.

— Brain metastases — present in ~50% over disease course; seizures, focal deficits, raised ICP.

— Tumor lysis syndrome — high tumor burden + rapid chemo response → hyperK, hyperphosphatemia, hyperuricemia, hypocalcemia, AKI.

— Hypercoagulability/VTE — Trousseau syndrome; ~10–15% lifetime risk.

— SIADH — severe symptomatic hyponatremia, seizures if Na <120.

— Ectopic Cushing — proximal weakness, hyperglycemia, hypokalemic alkalosis, infection susceptibility.

— LEMS — proximal weakness, autonomic dysfunction; treat underlying SCLC + 3,4-diaminopyridine.

— Paraneoplastic neurologic syndromes (anti-Hu encephalomyelitis, cerebellar degeneration) — often irreversible even with tumor control.

— Febrile neutropenia — sepsis risk; empiric broad-spectrum antibiotics within 1 hour, G-CSF for prophylaxis in high-risk regimens.

— Cisplatin nephrotoxicity, ototoxicity, peripheral neuropathy.

— Radiation esophagitis, pneumonitis, cardiac toxicity.

— Immune-related AEs: pneumonitis (life-threatening if missed — new dyspnea/cough on ICI = CT and steroids), colitis, hepatitis, endocrinopathies, myocarditis (rare but fatal).

— Secondary malignancies from etoposide (AML, MDS) — years later.

— PCI-related neurocognitive decline.

Step 3 management: Any SCLC patient on immunotherapy presenting with new dyspnea or hypoxia — obtain CT chest, rule out immune checkpoint pneumonitis vs infection vs progression vs PE; if pneumonitis ≥grade 2, hold ICI and start prednisone 1–2 mg/kg/day.

Disease-related complications:

Paraneoplastic complications:

Treatment-related complications:

When to Escalate Care — ICU, Consult, and Inpatient Triage

— Symptomatic SVC syndrome with airway or neurologic compromise.

— Suspected spinal cord compression (back pain + new weakness, sensory level, bowel/bladder dysfunction).

— Tumor lysis syndrome or high risk (bulky disease, high LDH) — start IVF, allopurinol/rasburicase.

— Symptomatic brain mets with seizures, focal deficits, raised ICP.

— Febrile neutropenia with hemodynamic instability, MASCC score <21, or comorbidities.

— Severe hyponatremia (Na <120 or symptomatic — seizures, altered mental status).

— Pericardial tamponade — ICU + cardiology for pericardiocentesis.

— Massive hemoptysis (>200 mL/24 hr) — IR or thoracic surgery consult.

— Hypercalcemic crisis (Ca >14 or symptomatic).

— Respiratory failure from airway obstruction, massive effusion, pneumonitis, or PE.

— Septic shock from neutropenic sepsis.

— Refractory tumor lysis with AKI requiring CRRT.

— ICI-related myocarditis with hemodynamic instability or arrhythmia.

— Status epilepticus from brain mets or limbic encephalitis.

— Medical oncology — to start systemic therapy ASAP (SCLC chemo can be lifesaving in SVC syndrome).

— Radiation oncology — for cord compression, brain mets, SVC, thoracic RT planning, PCI.

— Interventional pulmonology — EBUS biopsy, airway stenting, debulking.

— Interventional radiology — SVC stent, tunneled pleural/pericardial catheters, biopsy of difficult lesions.

— Thoracic surgery — rare resection candidates, pericardial window.

— Palliative care — early integration (Temel-style) improves QOL and may improve survival in advanced lung cancer; introduce at diagnosis of ES-SCLC.

— Smoking cessation counselor — continued smoking worsens outcomes even after diagnosis.

CCS pearl: In CCS, ordering "palliative care consult" early in ES-SCLC is a high-value, board-correct action — not a deferral of care but a parallel intervention alongside oncology.

Admit / inpatient triage criteria:

ICU criteria:

Consults to obtain early:

Key Differentials — Other Thoracic Malignancies

— Slower tempo, more often peripheral (adeno), can be central (squamous).

— Squamous more often causes hypercalcemia (PTHrP); SCLC more often causes SIADH/ectopic ACTH.

— Treated by TNM stage with surgery, chemo, immuno, targeted therapy based on molecular profile.

— Always order EGFR, ALK, ROS1, BRAF, KRAS, MET, RET, NTRK, PD-L1 on metastatic non-squamous NSCLC — molecular testing is standard, unlike SCLC.

— Shares neuroendocrine markers (synaptophysin, chromogranin) with SCLC.

— Larger cells, prominent nucleoli, lower N:C ratio.

— Often treated with SCLC-style platinum/etoposide if poorly differentiated.

— Indolent neuroendocrine tumors; younger patients, often non-smokers.

— Carcinoid syndrome (flushing, diarrhea, wheezing) rare unless liver mets.

— Surgically curable — fundamentally different prognosis and treatment from SCLC.

— Octreotide scan/Ga-68 DOTATATE PET rather than FDG-PET.

— B symptoms, bulky mediastinal adenopathy mimicking SCLC.

— Critical to biopsy before steroids — steroids lyse lymphoma cells, obscure diagnosis.

— Treated with rituximab-based chemo, very different prognosis.

Key distinction: Synaptophysin+/chromogranin+ on biopsy doesn't automatically mean SCLC — Ki-67 >50–80% and small-cell morphology distinguish SCLC from carcinoid (Ki-67 <20%). Treatment differs radically.

Non-small cell lung cancer (NSCLC) — adenocarcinoma, squamous, large cell:

Large-cell neuroendocrine carcinoma (LCNEC):

Pulmonary carcinoid (typical and atypical):

Pulmonary lymphoma (primary or secondary):

Thymoma/thymic carcinoma: anterior mediastinal mass; myasthenia gravis association (vs LEMS in SCLC).

Germ cell tumor (mediastinal): young men, elevated AFP/β-hCG; chemosensitive but distinct.

Mesothelioma: asbestos history, pleural rind, decreased lung volume on the affected side; biopsy via VATS.

Key Differentials — Non-Malignant Mimics

— Tuberculosis — apical cavitary disease, mediastinal adenopathy in immunocompromised; weight loss, night sweats overlap with SCLC. Acid-fast stain, IGRA, sputum culture, biopsy if needed.

— Endemic fungi (histoplasmosis, coccidioidomycosis, blastomycosis) — mass-like consolidation with hilar adenopathy; geography matters.

— Nocardia, actinomyces — chronic consolidation, sinus tracts.

— Pulmonary abscess — air-fluid level, fevers, foul sputum.

— Sarcoidosis — bilateral hilar adenopathy (vs unilateral bulky in SCLC), non-caseating granulomas; ACE level, biopsy.

— Granulomatosis with polyangiitis — cavitary nodules, sinus disease, hematuria, c-ANCA.

— IgG4-related disease — mass-like lesions, elevated IgG4.

— Solitary metastasis from extrathoracic primary (RCC, melanoma, breast, colon) — always image full body when a new lung mass is found.

— Hamartoma — popcorn calcification on CT, benign; doesn't enlarge rapidly.

— Carcinoid tumor — slow-growing endobronchial lesion.

— Pulmonary artery sarcoma — rare, mimics PE on imaging; FDG-avid.

— Mediastinal mass from aortic aneurysm — CT angiography distinguishes.

— Pituitary Cushing disease vs ectopic ACTH — high-dose dex suppression, IPSS, MRI pituitary; pituitary disease evolves over months-years, ectopic over weeks.

— Primary SIADH causes — CNS disease, drugs (SSRIs, carbamazepine), pneumonia.

— Autoimmune myasthenia gravis vs LEMS — MG worsens with effort, has ocular/bulbar symptoms, AChR antibodies; LEMS improves with effort, has autonomic features, anti-VGCC antibodies and SCLC association.

Board pearl: A patient with bilateral hilar adenopathy without a dominant mass is more likely sarcoidosis or lymphoma than SCLC — SCLC almost always has a dominant central mass.

Infectious:

Inflammatory/granulomatous:

Other neoplastic mimics:

Vascular/cardiac:

Paraneoplastic mimics:

Secondary Prevention, Discharge Plan, and Long-Term Therapy

— Continued smoking worsens chemo tolerance, radiation toxicity, second-primary risk, and survival.

— Offer varenicline, bupropion, or nicotine replacement + behavioral counseling.

— Document quit attempts at every visit — pay-for-performance metric.

— Antiemetics: ondansetron PRN, prochlorperazine; standing PPI if reflux.

— Bowel regimen — opioids + ondansetron → constipation; senna + docusate scheduled.

— Pain control — opioid stewardship, naloxone co-prescription, written taper plan.

— Anticoagulation — apixaban or rivaroxaban (or LMWH if GI tract concerns) for confirmed VTE; prophylactic anticoagulation not routine in ambulatory SCLC but consider in high-Khorana-score patients on chemo.

— Bone health — if bone mets, zoledronic acid or denosumab + calcium/vit D; dental clearance to reduce ONJ risk.

— Steroid taper if used for ICI toxicity or symptomatic brain mets — slow taper over 4–6 weeks.

— Antimicrobial prophylaxis: PJP prophylaxis (TMP-SMX) if on prednisone ≥20 mg/day for ≥4 weeks.

— Surveillance for second primary cancers (lung, head/neck, esophageal) — high baseline risk from shared tobacco etiology.

— Low-dose chest CT screening continues per USPSTF criteria for second primaries.

— Cardiovascular risk reduction — statin, BP control, A1c management (Step 3 longitudinal care).

— Neurocognitive support if PCI received.

Step 3 management: Document smoking cessation counseling at every SCLC follow-up visit — quality metrics and board questions both reward this.

Smoking cessation is the single highest-yield intervention even after diagnosis:

Discharge medications after first cycle / induction:

Vaccinations: influenza annually, COVID-19 boosters, pneumococcal (PCV20 or PCV15→PPSV23), RSV if ≥60, shingles (Shingrix) — non-live vaccines only. Avoid live vaccines (MMR, varicella, live zoster, BCG, yellow fever) on chemo and on ICIs.

Survivorship for LS-SCLC long-term responders:

Follow-Up, Monitoring Parameters, and Counseling

— CBC before each cycle; CMP including Mg, Ca, Cr; LDH as prognostic marker.

— Audiogram if cisplatin and baseline hearing concerns.

— TSH, ACTH/cortisol, glucose every 4–6 weeks on ICIs to catch endocrine irAEs early.

— Symptom-directed CT for response assessment after 2 cycles, then every 2–3 cycles; RECIST 1.1 criteria.

— MRI brain every 3 months if PCI deferred and active surveillance chosen.

— History, exam, CT chest/abdomen every 3 months for year 1–2, every 6 months years 3–5, then annually.

— MRI brain every 3–4 months for the first 1–2 years if no PCI.

— Annual low-dose CT indefinitely for second-primary lung cancer screening.

— Continue ICI until progression/toxicity; imaging every 6–9 weeks initially, then every 12 weeks.

— Routine labs and endocrine panel every cycle.

— Pulmonary rehab post-thoracic RT — improves dyspnea and functional capacity.

— Physical therapy for chemo-induced neuropathy and deconditioning.

— Nutrition consult — sarcopenia is independent prognostic factor.

— Mental health screening — depression and anxiety prevalent; PHQ-9 at follow-ups.

— Sexual health, fertility in younger patients — discuss before chemo.

— Advance care planning — POLST/MOLST, healthcare proxy, code status — revisit at each transition.

— Caregiver burden — assess and provide resources.

— Fever ≥38.0°C (100.4°F) → call/go to ED (neutropenia risk).

— New dyspnea, cough, diarrhea, jaundice on ICI → urgent contact.

— Red flag symptoms for recurrence: weight loss, persistent pain, new neuro symptoms.

Board pearl: Early integration of palliative care at the time of advanced lung cancer diagnosis improves quality of life and may extend survival (Temel et al., NEJM 2010) — a frequently tested concept.

During active treatment:

Post-treatment surveillance (LS-SCLC complete responders):

Post-treatment surveillance (ES-SCLC on maintenance ICI):

Rehabilitation and counseling:

Patient education:

Ethical, Legal, and Patient Safety Considerations

— Discuss realistic prognosis, including median survival numbers, in plain language with teach-back.

— PCI consent must explicitly include neurocognitive risks (memory, executive function), the option of MRI surveillance instead, and the patient's values around cognition vs cancer control.

— Document shared decision-making in the chart.

— Step 3 expects you to initiate these at diagnosis of ES-SCLC, not at end-of-life crisis.

— Use SPIKES or REMAP frameworks; involve family with patient's consent (HIPAA).

— Revisit at each disease transition (progression, hospitalization, new toxicity).

— Address before high-risk events (thoracic RT, ICU-level toxicity).

— Distinguish DNR/DNI from "do not treat" — patients can be DNR and still pursue chemo.

— Honor patient autonomy even if family disagrees; involve ethics consult if conflict.

— Discharge after a chemo admission is high-risk — neutropenia nadir occurs days 7–14, often at home.

— Provide written instructions, 24/7 oncology contact, thermometer, medication reconciliation, and scheduled follow-up within 7 days.

— Communicate with PCP via discharge summary including chemo regimen, last cycle date, expected nadirs, and red flags.

— Chemo dosing errors are a sentinel event class — verify BSA, AUC calculations, two-RN independent check, double-check with pharmacy.

— Look-alike sound-alike drugs (vincristine vs vinblastine, cisplatin vs carboplatin) — never intrathecal vincristine (fatal).

— Disclose medical errors per institutional policy; apology + plan.

— Cancer registry reporting is required.

Step 3 management: When a patient with advanced SCLC asks "How long do I have?", do not deflect — provide a range with uncertainty acknowledgment ("typically months to a year or two, but it varies"), then ask what hopes and concerns inform their question.

Informed consent for chemotherapy and PCI:

Goals-of-care conversations:

Code status and advance directives:

Transition-of-care safety:

Patient safety reporting:

Mandatory reporting and disclosure:

Equity considerations: Tobacco-related cancers disproportionately affect low-SES patients — screen for housing, food insecurity, transportation; refer to social work.

High-Yield Associations and Rapid-Fire Clinical Facts

— SIADH (hyponatremia) — ADH from tumor.

— Ectopic Cushing (hypokalemic alkalosis, hyperglycemia) — ACTH from tumor.

— LEMS (proximal weakness, dry mouth, areflexia improving with effort) — anti-VGCC antibodies.

— Plus anti-Hu paraneoplastic neurologic syndromes (limbic encephalitis, cerebellar degeneration).

Board pearl: "Hyponatremia + smoker + lung mass" = SIADH from SCLC. "Hypokalemic alkalosis + hyperglycemia + smoker + lung mass" = ectopic ACTH from SCLC. Pattern recognition wins these questions.

SCLC = smoking. Virtually never seen in lifelong nonsmokers (except EGFR-NSCLC transformation).

Central > peripheral — bulky hilar/mediastinal masses on CT.

Most common malignant cause of SVC syndrome in adults.

Paraneoplastic syndromes — memorize the SCLC trio:

Staging is binary in practice: limited vs extensive. TNM exists but rarely changes management.

MRI brain at diagnosis is mandatory — ~10–15% asymptomatic brain mets.

First-line LS-SCLC: concurrent cisplatin/etoposide + thoracic RT (45 Gy BID or 60–70 Gy daily) + PCI on response.

First-line ES-SCLC: platinum + etoposide + atezolizumab or durvalumab × 4, then maintenance ICI.

Surgery rare — only clinical T1-2N0M0 (<5%).

PCI reduces brain met incidence; consider in responders; weigh neurocognitive cost.

Relapse: platinum-sensitive (≥6 months) → re-challenge; platinum-resistant → lurbinectedin, topotecan, tarlatamab.

Tarlatamab = DLL3-targeted bispecific T-cell engager for relapsed ES-SCLC — newer, board-relevant.

Histology: small cells, scant cytoplasm, salt-and-pepper chromatin, nuclear molding, crush artifact; synaptophysin/chromogranin/CD56/INSM1/TTF-1 positive, Ki-67 >50%.

Molecular testing NOT standard in SCLC (unlike NSCLC).

LDH = independent prognostic marker.

Median OS: LS ~25–30 months; ES ~12–13 months.

Trousseau syndrome — migratory thrombophlebitis in mucin-producing cancers; SCLC also pro-thrombotic.

Combined small cell + NSCLC histology can occur — treat per the small cell component, the more aggressive driver.

Board Question Stem Patterns

Key distinction: When a Step 3 stem gives you SCLC + neuro symptoms, always image the brain before attributing symptoms to paraneoplastic disease.

Stem 1 — SIADH presentation: 65-yo M, 50 pack-years, 2-month cough/weight loss, Na 118, urine osm 450, serum osm 260, euvolemic. Best next step? → CT chest (→ biopsy → SCLC dx). Treat Na slowly with fluid restriction; chemo will resolve SIADH.

Stem 2 — SVC syndrome: Smoker with facial edema, distended neck veins, dyspnea worse leaning forward. Best initial step? → Contrast CT chest + tissue diagnosis; chemo is definitive treatment; SVC stent if airway/cerebral edema or refractory.

Stem 3 — Staging completeness: Newly diagnosed SCLC, CT C/A/P and PET show disease limited to one hemithorax. Next best step? → MRI brain with contrast (mandatory baseline).

Stem 4 — LEMS: 60-yo M, proximal leg weakness that improves after exercise, dry mouth, areflexia. Best next step? → CT chest to evaluate for SCLC (anti-VGCC antibody supports diagnosis but imaging finds the tumor).

Stem 5 — Ectopic ACTH: Smoker, 6 weeks of weakness, hypertension, hyperglycemia, K 2.8, HCO3 32, no cushingoid habitus yet (too fast). Best test? → ACTH (high), high-dose dex non-suppression, then chest imaging.

Stem 6 — Treatment choice LS-SCLC: Fit patient with LS-SCLC. Best initial therapy? → Concurrent cisplatin + etoposide + thoracic RT.

Stem 7 — Treatment choice ES-SCLC: Fit patient with ES-SCLC. Best initial therapy? → Carboplatin + etoposide + atezolizumab (or durvalumab).

Stem 8 — PCI decision: LS-SCLC with complete response after chemoRT. Next step? → Offer PCI (25 Gy/10 fx) after discussing neurocognitive risks.

Stem 9 — Relapsed disease: ES-SCLC patient relapses 8 months after first-line. Best next therapy? → Re-challenge with platinum/etoposide (platinum-sensitive); if <6 months → lurbinectedin or topotecan or tarlatamab.

Stem 10 — irAE: Patient on atezolizumab develops dyspnea, new bilateral infiltrates. Best step? → Hold ICI, rule out infection, start high-dose steroids for presumed pneumonitis.

Stem 11 — NSCLC transformation: EGFR-mutant NSCLC progressing on osimertinib with rapid LDH rise. Best step? → Rebiopsy looking for small-cell transformation.

One-Line Recap

Small cell lung cancer is an aggressive, tobacco-driven neuroendocrine malignancy treated by stage — concurrent platinum/etoposide + thoracic RT (and PCI on response) for limited-stage with curative intent, and platinum/etoposide + PD-L1 inhibitor followed by maintenance immunotherapy for extensive-stage with palliative intent — with constant attention to paraneoplastic syndromes, oncologic emergencies, and early palliative integration.

High-yield recap bullets:

Board pearl: When in doubt on a Step 3 SCLC stem, the highest-yield next steps are almost always "MRI brain," "start platinum/etoposide," "add immunotherapy if extensive-stage," or "early palliative care consult" — pattern-match accordingly.

Diagnosis: smoker + rapidly progressive central mass + paraneoplastic features (SIADH, ectopic ACTH, LEMS, anti-Hu) → tissue confirmation via EBUS or supraclavicular node; staging requires CT C/A/P + PET + MRI brain in every newly diagnosed patient.

Treatment by stage: LS-SCLC → cisplatin/etoposide + concurrent thoracic RT (45 Gy BID or 60–70 Gy daily), then PCI in responders. ES-SCLC → platinum/etoposide + atezolizumab or durvalumab × 4 cycles, then maintenance ICI. Surgery only for rare clinical T1-2N0M0 disease.

Emergencies and toxicities: SVC syndrome (chemo is the treatment), spinal cord compression (dex + RT), tumor lysis (hydrate, rasburicase), febrile neutropenia (abx within 1 hour), immune-related AEs (hold ICI + steroids for grade ≥2), and severe hyponatremia (correct slowly, ≤8–10 mEq/L/24 hr).

Longitudinal care: smoking cessation at every visit, palliative care from diagnosis of ES-SCLC, surveillance imaging every 3 months × 2 years then taper, annual low-dose CT for second primaries, vaccinate (non-live only), screen for depression and caregiver burden, and revisit goals of care at every disease transition — Step 3 rewards the longitudinal, ambulatory, system-level thinking around this otherwise aggressive cancer.